New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2014
07:16 EDTCANFCan-Fite BioPharma submits Phase II study protocol with CF102
Can-Fite BioPharma announced that a Phase II study protocol for the treatment of advanced liver cancer with its CF102 drug candidate has been submitted. The company plans to conduct the Phase II study in Israel, Europe and the US and will include 78 subjects with second-line treatment of advanced hepatocellular carcinoma with Child-Pugh Class B cirrhosis. The study will investigate the efficacy and safety of CF102 vs. placebo. The US Food and Drug Administration has granted Orphan Drug designation for CF102, for the treatment of hepatocellular carcinoma. According to Global Industry Analysts, the global liver cancer drug market is expected to exceed $2B by 2015.
News For CANF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 23, 2015
07:05 EDTCANFCan-Fite signs distribution agreement for CF101 with Cipher Pharmaceuticals
Can-Fite BioPharma (CANF) announced it has signed a distribution agreement with Cipher Pharmaceuticals (CPHR) to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals. Under the terms of the distribution agreement, Cipher is making an upfront payment of C$1.65M to Can-Fite. In addition, the agreement provides that additional payments of up to C$2M will be received by Can-Fite upon the achievement of certain milestones plus royalty payments of 16.5% of net sales of CF101 in Canada. The agreement further provides that Can-Fite will deliver finished product to Cipher. The timeline to regulatory submissions to Health Canada will be determined by the completion of the remaining clinical trial program. to Global Data, the psoriasis treatment market was worth $3.6 billion in 2010 and is forecast to grow to $6.7B by 2018. According to independent business information provider visiongain, the global rheumatoid arthritis drug market is expected to generate revenues of $38.5B in 2017.
March 18, 2015
07:03 EDTCANFCan-Fite BioPharma completes development of commercial biomarker test
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use